Please login to the form below
amphetamine and dextroamphetamine
This page shows the latest amphetamine and dextroamphetamine news and features for those working in and with pharma, biotech and healthcare.
Shire weathers generic Adderall XR challenge
attention deficit-hyperactivity disorder (ADHD) drug Adderall XR (amphetamine and dextroamphetamine). ... as well as Intuniv (guanfacine) - another ADHD drug - and treatment for hereditary angioedema Firazyr (icatibant).
Latest news
-
Shire's Q3 net profit doubles
Net profit for Shire recovers from payment to Acceleron and impairment charges relating to the divestment of Daytrana. ... Products that performed particularly well in the quarter included ADHD treatments Vyvanse (lisdexamfetamine) and Adderall XR
-
Shire ADHD scholarship programme
Applicants' work experience, volunteer/extracurricular activities, and academic transcripts will also be taken into account. ... use as adjunctive therapy to stimulants; the extended-release drug Vyvanse (lisdexamfetamine dimesylate), which was approved
-
New use cleared for Shire ADHD drug
The FDA has approved Shire's ADHD drug Intuniv for the new indication of adjunctive therapy to stimulants in children and adolescents aged six to 17. ... The company's ADHD portfolio also includes the extended-release drug VyVanse (lisdexamfetamine
More from news
Approximately 1 fully matching, plus 3 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 bonus benefits
-
Account Director – UK Office
-
Excellent salary and benefits
- Client Services Director- Flexible Working
-
Negotiable
-
Events Executive
-
DOE
- Account Manager – Healthcare advertising
-
Salary TBC
Subscribe to our email news alerts
- Novartis eyes potential new indication for Cosentyx
- J&J's Tremfya filed for approval in US for psoriatic arthritis
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Lucid Group increases footprint in UK, Asia Pacific and Middle East with the acquisition of HealthCare21
- AZ, Merck’s Lynparza scores market-expanding clinical success
- Gracell reports impressive data with one-day CAR-T for leukaemia
- Pharma industry consensus: fix data strategy before pushing artificial intelligence and machine learning applications
- Zenopa delivers Communiqué prizes to winners
- Detecting Alzheimer’s ahead of a cure
- When it’s OK to not be OK: Bedrock breaks down mental health stigma
- Roche wins FDA breakthrough for Gazyva in lupus nephritis
- Programmatic methodology and why you should be using it
PMHub
OPEN Health
OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...
Latest intelligence
- Detecting Alzheimer’s ahead of a cure
- A focus on promising new research...
- Programmatic methodology and why you should be using it
- What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...
- Can you survive without the blue dot?
- Or has the digital world has replaced our brain...
Quick links
Infographics
